PMID- 16771784
OWN - NLM
STAT- MEDLINE
DCOM- 20060809
LR  - 20171116
IS  - 0905-6157 (Print)
IS  - 0905-6157 (Linking)
VI  - 17
IP  - 4
DP  - 2006 Jun
TI  - Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its 
      relationship with disease severity in pediatric age.
PG  - 297-303
AB  - CD30 is a transmembrane molecule that may be expressed on a proportion of 
      activated T-lymphocytes and has been reported to be a marker of Th2 phenotype. A 
      soluble form of CD30 (sCD30) is released by CD30+ cells in vivo. Our objective 
      was to evaluate serum sCD30 levels in children with atopic dermatitis (AD) or 
      bronchial asthma and to investigate its relation to disease severity. This study 
      included of 60 infants and children, of whom 18 had AD, 22 had bronchial asthma 
      and 20 were healthy matched subjects. Severity of AD was assessed according to 
      the objective Scoring Atopic Dermatitis (obj-SCORAD) index. Laboratory 
      investigations included complete blood count, serum total immunoglobulin E (IgE) 
      and serum sCD30 by ELISA. Serum levels of sCD30 in AD (77.7+/-27.9 U/ml) and 
      asthmatic patients (49.2+/-21.5 U/ml) were significantly increased compared with 
      the control group (18.2+/-7.0 U/ml) (t=8.8, p<0.0001; t=6.4, p<0.0001, 
      respectively). In patients with AD, sCD30 levels were shown to correlate with 
      obj-SCORAD (r=0.96, p<0.0001). Patients with moderate persistent asthma had 
      significantly elevated sCD30 levels than those with mild persistent asthma 
      (t=3.4, p<0.01). In addition, sCD30 was inversely correlated to peak expiratory 
      flow rate (r=-0.78, p<0.0001). Levels of sCD30 did not correlate with age, 
      disease duration or serum total IgE (p>0.05). In conclusion, serum sCD30 levels 
      correlate with the severity of AD and bronchial asthma. It appears to be an 
      additional objective marker that may be useful for follow up and may help to 
      improve research and management of these diseases.
FAU - Heshmat, Nahla M
AU  - Heshmat NM
AD  - Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, 
      Egypt. nahla_heshmat@hotmail.com
FAU - El-Hadidi, Eman S
AU  - El-Hadidi ES
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Pediatr Allergy Immunol
JT  - Pediatric allergy and immunology : official publication of the European Society 
      of Pediatric Allergy and Immunology
JID - 9106718
RN  - 0 (Biomarkers)
RN  - 0 (Ki-1 Antigen)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Asthma/*blood/immunology
MH  - Biomarkers/blood
MH  - Child
MH  - Child, Preschool
MH  - Dermatitis, Atopic/*blood/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Infant
MH  - Ki-1 Antigen/*blood
MH  - Male
MH  - Reference Values
MH  - *Severity of Illness Index
MH  - Sex Factors
MH  - Solubility
MH  - Time Factors
EDAT- 2006/06/15 09:00
MHDA- 2006/08/10 09:00
CRDT- 2006/06/15 09:00
PHST- 2006/06/15 09:00 [pubmed]
PHST- 2006/08/10 09:00 [medline]
PHST- 2006/06/15 09:00 [entrez]
AID - PAI405 [pii]
AID - 10.1111/j.1399-3038.2006.00405.x [doi]
PST - ppublish
SO  - Pediatr Allergy Immunol. 2006 Jun;17(4):297-303. doi: 
      10.1111/j.1399-3038.2006.00405.x.